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of the dipetide Ala-Gln and the amino acids glutamine, citrulline and arginine,
with the administration of Ala-Gln in preoperative patients
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Enhancement of depressed plasma concentrations of glutamine and arginine is associated with better clinical outcome. Supplementation of glutamine might
be a way to provide the patient with glutamine, and also arginine, because glutamine provides the kidney with citrulline, from which the kidney produces
arginine when plasma levels of arginine are low. The aim of the present study was to investigate the parenteral and enteral response of the administered
dipeptide Ala-Gln, glutamine, citrulline and arginine. Therefore, seven patients received 20 g Ala-Gln, administered over 4 h, parenterally or enterally, on
two separate occasions. Arterial blood samples were taken before and during the administration of Ala-Gln. ANOVA and a paired t test were used to test
differences (P,0·05). Ala-Gln was undetectable with enteral administration, whereas Ala-Gln remained stable at a plasma concentration of 268mmol/l
throughout parenteral infusion and rapidly decreased towards zero after infusion was stopped. The highest level of glutamine was observed with parenteral
infusion of the dipeptide, although enteral infusion also significantly increased plasma levels of glutamine. The highest plasma response of citrulline was
observed with the enteral administration of the dipeptide, although parenteral administration also increased plasma levels of citrulline. Plasma arginine
increased significantly with parenteral infusion, but not with enteral administration of Ala-Gln. In conclusion, administrations of Ala-Gln, parenteral or ent-
eral, resulted in an increased plasma glutamine response, as compared with baseline. Interestingly, in spite of the high availability of citrulline with enteral
administration of the dipeptide, only parenteral infusion of Ala-Gln increased plasma arginine concentration.
Ala-Gln: Glutamine: Citrulline: Arginine: Parenteral nutrition: Enteral nutrition
The benefit of nutritional support in critically ill patients has been
the subject of extensive study in recent years. The reason is
that the intensive care population has a high prevalence of dis-
ease-related malnutrition (.40 %), which is associated with an
increased morbidity and mortality (Giner et al. 1996).
Next to improvement of food policy on the intensive care unit,
including early, preferably enteral, feeding of an optimal dose of
energy and protein, special formulas have been designed with an
enrichment of certain nutrients to enhance recovery, based on
their biological properties.
Within this scope, formulas enriched with the amino acids argi-
nine and glutamine were developed. Both amino acids have been
proven to enhance the immune system and improve organ func-
tion (Murphy & Newsholme, 1998; Newsholme, 2001; Rodriguez
et al. 2002; Ziegler et al. 2003).
However, arginine supplementation for the critically ill is cur-
rently under debate, because a sub-analysis within a meta-analysis
of twenty-two clinical trials showed a tendency (P¼0·051)
towards an increase in mortality in septic patients (Heyland
et al. 2001). This finding was confirmed in a recent randomised
multicentre trial with patients having severe sepsis (Bertolini
et al. 2003). There was significantly higher mortality in patients
receiving enteral arginine-enriched nutrition compared with
patients receiving parenteral nutrition.
Hypothetically, supplementation of the amino acid glutamine,
an indirect precursor for arginine, might be a more physiological
way to generate arginine, because synthesis is regulated by the
kidney, and only low levels of arginine trigger synthesis (Prins
et al. 1999). The kidney is the most important organ for endogen-
ous arginine synthesis, where it is metabolised from citrulline
(Wu & Morris, 1998). Citrulline in turn is predominantly metab-
olised in the intestine from either glutamine or arginine
(Windmueller & Spaeth, 1981; Cynober et al. 1995; Wu &
Morris, 1998). Houdijk et al. (1994) showed in an experimental
rat model that a glutamine-enriched enteral diet increased
plasma arginine concentrations by increasing renal arginine pro-
duction. This finding was confirmed in a randomised clinical
trial with trauma patients, who expressed a low plasma arginine
concentration. A glutamine-enriched enteral feeding normalised
plasma arginine concentrations within a couple of days (Houdijk
et al. 1998).
The subject of the present study was the relationship between
arginine and glutamine. Considering the importance of enteral
glutamine metabolism in endogenous arginine synthesis, we
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investigated how the route of feeding, either parenterally or enter-
ally, affected plasma concentrations of glutamine, citrulline and
arginine. Therefore, we compared a 4 h continuous parenteral
infusion with a 4 h enteral administration of the dipeptide Ala-
Gln (Furst, 1998). Furthermore, we investigated if there was a
difference between the plasma concentration of the dipeptide
during parenteral or enteral supply.
Patients and methods
Patients
Seven patients undergoing liver resection for metastatic colorectal
cancer in the VU University Medical Centre, Amsterdam, The
Netherlands, were included in the present study. Patients between
35 and 75 years were considered eligible for the study. Exclusion
criteria were pregnancy, unfitness for surgery, use of corticoster-
oids 4 weeks before surgery, insulin-dependent diabetes mellitus,
Coeliac or Crohn’s disease or another major cause of intestinal
malabsorption.
Patients’ characteristics are given in Table 1. The BMI of
patients did not reveal malnourishment. Patients were considered
to be at risk for malnourishment if BMI was ,20 kg/m2 (Elia &
Lunn, 1997). All patients expressed a slightly increased level of
g-glutamyl-transferase in plasma (92 (SE 34) U/l) before the
study. However, transaminases and bilirubin were not enhanced
in any of the patients and, thus, liver function was considered
to be normal. Furthermore, none of the patients demonstrated
malfunction of the kidney, judged by plasma creatinine and
urea concentrations.
Informed consent was obtained from all patients before
inclusion and the study protocol was approved by the ethical com-
mittee of the VU University Medical Centre.
Study design
Patients were admitted to the hospital 3 d before surgery. Height
and weight were recorded and BMI was calculated. Furthermore,
liver enzymes and renal function were observed before the start of
the study, since both organs are involved in the observed meta-
bolism of glutamine, citrulline and arginine.
All patients received a parenteral or enteral solution of Ala-Gln
(Dipeptivenw; Fresenius Kabi, Bad Homburg, Germany) on two
separate occasions, on two consecutive days. For the enteral
route all patients received a self-propelling nasojejunal tube
(Bengmarkw; Nutricia, Zoetermeer, The Netherlands). The pH
was measured immediately after insertion to check if the tube
was properly placed in the stomach (pH , 2) and an X-ray of
the abdomen was made 1 d after insertion to check if the tube
had migrated to the jejunum. For the parenteral route an intrave-
nous line was placed in the forearm. Patients received the solution
parenterally 2 d before surgery and enterally on the day before
surgery. Patients received the solutions in the morning after over-
night fasting. Water was allowed ad libitum. Patients were not
allowed to eat or drink other beverages after 20.00 hours on the
evening before the parenteral or enteral administration of Ala-
Gln. Furthermore, coffee, tea and sleep-inducing medication
were not allowed.
Infusion protocol
The continuous 4 h administration of 100 ml Dipeptivenw
(Fresenius Kabi) containing 20 g the dipeptide Ala-Gln, dissolved
in 400 ml 0·9 % NaCl was started between 08.00 and 10.00 hours,
either parenterally or enterally on two separate occasions, on two
consecutive days. Administration rate was 23 mmol Ala-Gln/h.
Arterial blood samples were taken before the start and at 15, 30,
45, 60, 90, 120, 180, 240, 250, 260 and 270 min after start
of administration. The last three samples (250, 260, 270 min)
were obtained after the solution was administered, to study the
decay curve.
Preparation of blood samples
Blood was collected in heparin tubes and directly put on ice.
Samples were centrifuged within 15 min after collection, for
10 min at 2000 g in a 48C cooled centrifuge. Two portions of
500ml plasma of each sample were put in two cryovials with
20 mg dry sulfosalicyclic acid for deproteinising, vortexed,
frozen in liquid N2 and kept at 2808C until analysis.
Amino acid analysis
The concentrations of free amino acids were determined using a
reverse-phase HPLC as previously described (Teerlink et al.
1994). The plasma concentration of the Ala-Gln was determined
using ion-exchange chromatography and spectrometric detection
after ninhydrin derivatisation (Neveux et al. 2004) on an auto-
matic analyser (Jeol Aminotac JLC-500V analyzer; Jeol,
Croissy-sur-Seine, France). The manufacturer’s onboard program
(Physio C) was adapted to enable adequate separation of the
dipeptide (J. Jonte, T. Popovici, J.P. De Bandt and L. Cynober,
unpublished results).
Statistical analysis
Data are expressed as means with their standard errors. Distri-
butions of Ala-Gln and free amino acid concentrations in samples,
drawn at different points in time, were checked for normality
using the Shapiro–Wilks test. Because data were normally dis-
tributed, one-way ANOVA for repeated measures was performed.
If ANOVA was significant, a paired t test was performed to com-
pare means of amino acid concentrations at different points in
time with baseline (sample taken before the start of administration
of Ala-Gln) and to compare means of amino acid concentrations
obtained during enteral or parenteral administration at the corre-
sponding points in time, on the two consecutive days. P,0·05
was considered significant. SPSS 9·0 for Windowsw (SPSS Inc.,
Table 1. Patient characteristics
(Mean values with their standard errors)
Mean SE
Males (n) 5
Females (n) 2
Age (years) 63 2
Weight (kg) 88 6
Height (cm) 177 6
BMI (kg/m2) 29 3
For details of procedures, see p. 20.
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Chicago, IL, USA) was used to perform the statistical
calculations.
Results
No complaints or side effects were observed during parenteral or
enteral administration of Ala-Gln.
Plasma dipeptide concentration
Patients received on average 269 (SE 21) mmol Ala-Gln/h per kg
parenterally or enterally during 4 h on two separate occasions, on
two consecutive days. When Ala-Gln was infused parenterally,
the plasma concentration of Ala-Gln reached a concentration of
262 (SE 27) mmol/l at 60 min. Thereafter plasma concentration
remained stable at an average concentration of 260mmol/l
throughout infusion. After finishing infusion, at 240 min,
plasma concentration of Ala-Gln rapidly decreased towards
zero (Fig. 1).
Enteral administration of Ala-Gln, on the other hand, did not
result in a detectable plasma concentration of Ala-Gln. This
difference between the enteral and parenteral route was significant
from 30 to 250 min.
Plasma glutamine concentration
Administration of Ala-Gln resulted in a significant increase in the
plasma concentration of the constituent amino acids glutamine
and alanine with both parenteral and enteral administration. Base-
line plasma glutamine concentrations were 585 (SE 51) mmol/l
(parenteral) and 581 (SE 20) mmol/l (enteral) (NS). Both feeding
routes resulted in a significant increment in plasma glutamine
response in time. During the parenteral infusion, plasma
glutamine concentrations were higher than baseline at 15 min
and still higher at 270 min after start of infusion, with a peak
increment of 468 (SE 57) mmol/l at 240 min. During the enteral
administration, plasma glutamine was significantly higher than
baseline from 30 to 260 min, with a peak increment of 207 (SE
42) mmol/l at 90 min. A comparison of enteral with parenteral
administration at the corresponding points in time showed that
plasma glutamine was significantly higher with parenteral infu-
sion from 60 to 270 min (Fig. 2).
Plasma glutamate concentration
The plasma concentration of glutamate, the intermediary metab-
olite in the glutamine to citrulline pathway, did not change with
parenteral infusion as compared with baseline. During enteral
administration, plasma glutamate concentration increased signifi-
cantly from 45 to 260 min. This difference between enteral and
parenteral administration was significant at 60, 120 and 240 min
(Fig. 3).
Plasma citrulline concentration
During parenteral or enteral administration of Ala-Gln, plasma
citrulline concentrations were significantly higher than baseline
from 45 to 260 min. Plasma citrulline response was significantly
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Fig. 1. Graphic illustration of plasma Ala-Gln response with parenteral (-O-)
or enteral (-†-) infusion of Ala-Gln. Mean value was significantly different
from that at baseline (*P,0·05). Mean value for parenteral nutrition was sig-
nificantly different from that for enteral nutrition (†P,0·05).
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Fig. 2. Graphic illustration of plasma glutamine (Gln) response with parent-
eral (-O-) or enteral (-†-) infusion of Ala-Gln. Mean value was significantly
different from that at baseline (*P,0·05). Mean value for parenteral nutrition
was significantly different from that for enteral nutrition (†P,0·05).
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Fig. 3. Graphic illustration of plasma glutamate (Glu) response with parent-
eral (-O-) or enteral (-†-) infusion of Ala-Gln. Mean value was significantly
different from that at baseline (*P,0·05). Mean value for parenteral nutrition
was significantly different from that for enteral nutrition (†P,0·05).
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higher from 120 to 270 min during enteral infusion when com-
pared with parenteral infusion (Fig. 4).
Plasma arginine concentration
During parenteral infusion a slight but significant increment in
plasma arginine response in time was observed. Plasma arginine
was higher than baseline from 30 to 180 min. A comparison of
enteral with parenteral administration at the corresponding
points in time did not reveal any difference (Fig. 5).
Plasma concentrations of other amino acids
Kinetics of other amino acids were studied as well (Tables 2
and 3). This resulted in some interesting observations, which
are summarised later.
The plasma concentration of the non-essential amino acid taur-
ine increased significantly with parenteral infusion of Ala-Gln.
Enteral infusion of Ala-Gln did not affect plasma taurine
concentration.
The essential amino acids phenylalanine, isoleucine, tyrosine,
valine, tryptophan and leucine and the non-essential amino acid
glycine decreased with both parenteral and enteral infusion.
A comparison of enteral and parenteral infusions at the corre-
sponding points in time showed that plasma valine concentration
decreased more during parenteral infusion than during enteral
infusion.
Discussion
The goal of the present study was to investigate the plasma
response of glutamine, citrulline and arginine to parenteral or ent-
eral supply of Ala-Gln. Importantly, we found that both feeding
routes increased plasma concentrations of glutamine and citrulline
to a different extent and that plasma arginine concentration only
increased with parenteral infusion of Ala-Gln. These results
show that the metabolic pathway from glutamine to citrulline
and arginine is affected by the feeding route. This suggests that
the choice of how to feed patients – enterally or parenterally –
also needs to be based on the metabolic effect of either route.
The chronological order of the metabolic pathway from glutamine
to arginine, starting with the metabolic handling of the dipeptide,
will be followed in the discussion of the results and their rel-
evance for the clinical practice.
Ala-Gln is a practical way to provide glutamine parenterally
(Albers et al. 1988, 1989; Hubl et al. 1989; Lochs et al. 1990).
Not much is known about the fate of enterally supplied Ala-
Gln. The present study proved that glutamine derived from enter-
ally supplied Ala-Gln reaches the systemic circulation, although
the plasma response of glutamine was more pronounced with par-
enteral administration. Enterally supplied Ala-Gln was comple-
tely hydrolysed, which was demonstrated by the undetectable
low concentration of the dipeptide. This is an observation that
has not been described before. However, absorption
and subsequent hydrolysis of dipeptides has been studied exten-
sively in the past. Therefore, enterally supplied Ala-Gln was
most probably either hydrolysed on the surface of the intestinal
mucosal cell or taken up in one piece, followed by intracellular
hydrolysis or by hydrolysis in the liver (Silk, 1974; Minami
et al. 1992). In contrast, Ala-Gln was detectable in plasma
during parenteral infusion. Patients received on average 269 (SE
21) mmol Ala-Gln/h per kg, a rate of infusion higher than in
other studies. For instance, Lochs et al. (1990) infused
100mmol/h per kg and Albers et al. (1989) 110mmol/h per kg
parenterally. This might explain the difference between the
level of Ala-Gln at steady state during parenteral infusion in the
present study, when compared with the levels in these other
studies: the plasma concentration of Ala-Gln remained stable at
an average concentration of 268mmol/l in the present study,
while Lochs et al. (1990) observed a steady state at 70mmol/l
and Albers et al. (1989) at 50mmol/l, during continuous parent-
eral infusion. Anyhow, the steady state and the rapid decrease
of levels of Ala-Gln towards zero, after infusion was finished,
showed that parenterally infused Ala-Gln did not accumulate in
the body.
A large part of glutamine derived from the enterally adminis-
tered Ala-Gln was probably metabolised in the splanchnic area,
which can be suggested from the lower plasma glutamine response
to enteral administration. This might be explained by the import-
ance of glutamine as a major fuel and nucleotide substrate for
the gut and the gut-associated immune system (Scheppach et al.
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Fig. 4. Graphic illustration of plasma citrulline (Cit) response with parenteral
(-O-) or enteral (-†-) infusion of Ala-Gln. Mean value was significantly differ-
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1994; McCauley et al. 1998; Wiren et al. 1998). Previous studies
have shown that the total splanchnic use of enterally supplied glu-
tamine is likely to represent 50–70 % of glutamine load (Darmaun
et al. 1986; Matthews et al. 1993). Also, glutamine is used for glu-
coneogenesis by the liver in the fasting state (Souba, 1992) and was
likely to be used by the tumour in the patients studied here (Souba,
1992; Dudrick et al. 1993; Espat et al. 1995). It is not clear how
much glutamine was used by the tumour in these patients. Ridge
et al. (1987) have described how colorectal metastasis extracts as
much glutamine as a comparable amount of liver tissue when glu-
tamine is provided by the hepatic artery. Furthermore, they
described that less glutamine is extracted when glutamine is
offered by the portal vein, which was the case in the present
study by the enteral route. In the present study, baseline values
of glutamine were within the range of what is considered to be
normal and levels of glutamine were largely elevated with parent-
eral administration of glutamine, despite the positive uptake in the
tumour. We therefore estimate the uptake by the tumour to be
small. The metabolism of enterally supplied glutamine in the
splanchnic area was furthermore reflected by the plasma response
of glutamate and citrulline. Glutamate increased with the enteral
but not with the parenteral route of administration. This increment
in the plasma glutamate concentration might contribute to the ben-
eficial effect of enterally supplied glutamine on gut integrity (van
der Hulst et al. 1993), because deamidation of glutamine into
glutamate is required to reduce the paracellular permeability of
the gut mucosa (Le Bacquer et al. 2003). The finding that gluta-
mine is largely metabolised in the splanchnic area suggests that
in case of severe depression of the glutamine content in blood, ent-
eral supplementation might need to be combined with parenteral
supplementation of glutamine, in order to have more than a local
effect on the permeability of the intestine and the gut surrounding
the immune system.
As for citrulline, the results from the present study indicate
that enterally supplied glutamine serves indeed as a precursor
for citrulline in the intestine. Despite the more pronounced
increase in levels of citrulline with enterally supplied Ala-Gln,
arginine levels did not increase with enteral supply of Ala-Gln.
In contrast, despite the lower plasma response of citrulline,
plasma levels of arginine did increase with parenteral supply
of Ala-Gln. Houdijk et al. (1998) showed that glutamine-
enriched enteral nutrition normalised plasma arginine concen-
tration in trauma patients with low plasma arginine levels at
the onset of the trial (56 (SD 25)mmol/l). Patients from the
present study expressed already slightly elevated plasma concen-
trations of arginine (105 (SE 11) mmol/l) at the start of the study.
Therefore, plasma arginine concentrations were not likely to trig-
ger arginine production from citrulline by the kidney. This result
suggests that the enteral route might be preferable to the parent-
eral route in critically ill patients. However, the present study
does not prove that the parenterally provided glutamine was con-
verted into arginine. To elucidate this, a study design involving
stable isotopes is required.
As for the other amino acids, a slight but significant increase in
plasma concentrations of taurine was observed during parenteral
infusion. Glutamine might be regulative in taurine metabolism,
because Boelens et al. (2003) observed an increase in
plasma taurine concentrations in trauma patients who received
glutamine-enriched enteral nutrition. However, the relationship
between glutamine and taurine remains to be elucidated, and is
likely to be different under circumstances of critical illness.
Almost all concentrations of essential amino acids decreased
with both administrations of Ala-Gln. This is most certainly due
to the restriction of a normal diet for 16 h, since essential
amino acids need to be ingested by nutrition.
In conclusion, interesting differences were observed in plasma
responses of glutamine, citrulline and arginine to parenteral or
enteral administration of Ala-Gln in preoperative patients,
suggesting that the choice of feeding route results in different
metabolic handling of glutamine. Important is that both enteral
and parenteral administration of Ala-Gln resulted in a higher
plasma glutamine concentration, which suggests that enteral
supply of Ala-Gln might be useful in clinical practice.
The splanchnic metabolism of enterally supplied Ala-Gln was
suggested by the absence of Ala-Gln in plasma, less pronounced
increase in plasma concentrations of glutamine and more pro-
nounced increase in plasma concentrations of glutamate and
citrulline with enteral administration, as compared with parenteral
infusion. Splanchnic metabolism of glutamine might contribute to
the beneficial effects of glutamine-enriched enteral nutrition on
gut integrity. Since critically ill patients are more prone to infec-
tions, this might be a reason to provide at least a part of the sup-
plementary glutamine by the enteral route.
Furthermore, parenteral infusion of Ala-Gln increased the plasma
arginine concentration, whereas enteral supply did not increase
plasma arginine levels, despite an abundance of citrulline. Further
exploration of the observed differences is warranted, considering
the concern about possible harmful side effects of arginine.
Within this scope, it might be necessary to investigate the pathway
from glutamine to arginine with the help of stable isotopes.
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